$29.00
Manufacturer: Romania
Viral infections caused by herpes simplex virus type 1 and 2, chickenpox virus, cytomegalovirus, Epstein-Barr virus, measles virus, mumps virus, including in patients with immunodeficiency conditions; viral respiratory infection; papillomavirus infection of the skin and mucous membranes: genital warts, papillomavirus infection of the vulva, vagina and cervix (as part of complex therapy); acute viral encephalitis (as part of complex therapy); viral hepatitis (as part of complex therapy); subacute sclerosing panencephalitis (as part of complex therapy).
Description
GROPRINOZIN SYRUP COMPOSITION
active substance: inosine pranobex; 5 ml of syrup contains 250 mg of inosine pranobex; auxiliary substances: methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), sucrose, sodium hydroxide (E 524), citric acid (E 330), purified water.
GROPRINOZIN SYRUP DOSAGE FORM
Syrup. Basic physical and chemical properties: clear liquid with a sweet taste.
GROPRINOZIN SYRUP PHARMACO-THERAPEUTIC GROUP
Antiviral drugs for systemic use. ATX code J05A X05.
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics. Groprinosin-Richter is an antiviral agent with immunomodulatory properties. The drug normalizes (in an individual norm) deficiency or dysfunction of cellular immunity, inducing maturation and differentiation of T-lymphocytes and T1-helpers, potentiating the induction of lymphoproliferative responses in mitogen or antigenically active cells. Inosine pranobex simulates the cytotoxicity of T-lymphocytes and natural killer cells, the function of CD8 and CD4, and also increases the amount of immunoglobulin G and additional surface markers of the compliment. Inosine pranobex enhances the synthesis of interleukin-1 (IL-1) and the synthesis of interleukin-2 (IL-2) by regulating the expression of IL-2 receptors. Inosine pranobex significantly increases the secretion of endogenous interferon gamma and reduces the production of interleukin-4 in the body. Inosine pranobex enhances the action of neutrophils, chemotaxis and phagocytosis of monocytes and macrophages. Inosine pranobex inhibits the synthesis of the virus by incorporating inosine-orotic acid into the polyribosomes of the cell affected by the virus and inhibits the attachment of adenylic acid to the viral m-RNA.
INDICATIONS
Viral infections caused by herpes simplex virus types 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, measles virus, mumps virus, including in patients with immunodeficiency states; viral respiratory infections; papillomavirus infection of the skin and mucous membranes: genital warts, papillomavirus infection of the vulva, vagina and cervix (as part of complex therapy); acute viral encephalitis (as part of complex therapy); viral hepatitis (as part of complex therapy); subacute sclerosing panencephalitis (as part of complex therapy).
CONTRAINDICATIONS GROPRINOSIN-RICHTER
Hypersensitivity to the active substance or to any of the excipients of the drug, gout, hyperuricemia.
Recent Reviews